Soleno Therapeutics, Inc.
SLNO
$48.12
-$0.91-1.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.02M | 32.66M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.02M | 32.66M | -- | -- | -- |
| Cost of Revenue | 1.14M | 696.00K | -- | -- | -- |
| Gross Profit | 64.88M | 31.96M | -- | -- | -- |
| SG&A Expenses | 33.75M | 28.24M | 29.26M | 37.30M | 49.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.30M | 38.08M | 42.78M | 58.79M | 79.34M |
| Operating Income | 22.72M | -5.42M | -42.78M | -58.79M | -79.34M |
| Income Before Tax | 26.01M | -4.71M | -43.77M | -55.98M | -76.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.01M | -4.71M | -43.77M | -55.98M | -76.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.01M | -4.71M | -43.77M | -55.98M | -76.62M |
| EBIT | 22.72M | -5.42M | -42.78M | -58.79M | -79.34M |
| EBITDA | 23.22M | -4.92M | -42.27M | -58.29M | -78.84M |
| EPS Basic | 0.49 | -0.09 | -0.95 | -1.27 | -1.83 |
| Normalized Basic EPS | 0.31 | -0.04 | -0.55 | -0.79 | -1.13 |
| EPS Diluted | 0.47 | -0.09 | -0.95 | -1.27 | -1.83 |
| Normalized Diluted EPS | 0.30 | -0.04 | -0.55 | -0.79 | -1.13 |
| Average Basic Shares Outstanding | 53.33M | 50.48M | 46.18M | 43.92M | 41.88M |
| Average Diluted Shares Outstanding | 54.92M | 50.48M | 46.18M | 43.92M | 41.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |